Roth Capital raised the firm’s price target on CervoMed (CRVO) to $20 from $16 and keeps a Buy rating on the shares. Following a re-analysis of the Phase 2b results, Roth is “convinced” that CervoMed’s neflamapimod has the potential to become a new therapy for dementia with Lewy bodies. The firm increased the drug’s probability of success to 50% from 40%, prompting the higher price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Unveils Promising Phase 2b Trial Results
- CervoMed’s Strategic Advancements in Clinical Trials Justify Buy Rating
- CervoMed announce new data from Phase 2b trial of RewinD-LB
- CervoMed appoints Matthew Winton as chief commercial, business officer
- CervoMed announces development program, benefits of neflamapimod